SANA BIOTECHNOLOGY INC. news, videos and press releases
For more news please use our advanced search feature.
SANA BIOTECHNOLOGY INC. - More news...
SANA BIOTECHNOLOGY INC. - More news...
- Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
- Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
- Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
- Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
- Sana Biotechnology to Present at December 2024 Investor Conferences
- Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
- Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
- Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
- Sana Biotechnology to Present at September 2024 Investor Conferences
- Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
- Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates
- Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
- Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
- Sana Biotechnology to Present at May and June 2024 Investor Conferences
- Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
- Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
- Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Sana Biotechnology Announces Pricing of Upsized Public Offering
- Sana Biotechnology Announces Proposed Public Offering of Common Stock
- Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
- Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
- Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
- Sana Biotechnology to Present at November and December 2023 Investor Conferences
- Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
- Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
- Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
- Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
